Gridelli Cesare, Maione Paolo, Galetta Domenico, Colantuoni Guiseppe, Del Gaizo Filomena, Ferrara Carmine, Guerriero Ciro, Nicolella Dario, Rossi Antonio
Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy.
J Thorac Oncol. 2007 Aug;2(8):758-61. doi: 10.1097/JTO.0b013e3180cc25b0.
We report the cases of three patients with advanced non-small cell lung cancer responding to erlotinib after progression under gefitinib treatment.
Three never-smoker women with advanced lung adenocarcinoma, two pretreated with chemotherapy and with gefitinib and one with gefitinib alone, received erlotinib in a daily dose of 150 mg. All three patients had disease progression and had achieved tumor control with gefitinib.
The first patient achieved partial response of lung lesions, the second had partial response of brain lesions and stable disease of lung and bone disease, and the third had partial response of brain lesions and stable disease of lung disease. At the time of this analysis, all three patients were still receiving treatment with erlotinib with no evidence of treatment failure after more than 13, 13, and 7 months, respectively. Erlotinib was generally well tolerated, with grade 1 skin toxicity recorded in two patients.
Erlotinib may be effective in patients with non-small cell lung cancer who were previously and successfully treated with gefitinib. However, careful selection of these patients is needed.
我们报告了3例晚期非小细胞肺癌患者在吉非替尼治疗进展后对厄洛替尼产生反应的病例。
3例从不吸烟的晚期肺腺癌女性患者，2例曾接受化疗和吉非替尼治疗，1例仅接受吉非替尼治疗，接受每日剂量150 mg的厄洛替尼治疗。所有3例患者均出现疾病进展，且曾通过吉非替尼实现肿瘤控制。
第1例患者肺部病变获得部分缓解，第2例患者脑部病变获得部分缓解，肺部和骨部疾病病情稳定，第3例患者脑部病变获得部分缓解，肺部疾病病情稳定。在本次分析时，所有3例患者仍在接受厄洛替尼治疗，分别在超过13、13和7个月后均无治疗失败的迹象。厄洛替尼总体耐受性良好，2例患者记录有1级皮肤毒性。
厄洛替尼可能对先前接受过吉非替尼治疗且治疗成功的非小细胞肺癌患者有效。然而，需要仔细挑选这些患者。
